HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business (Health)

Set Alert for Business {Health}

HRA Pharma Sharpens Focus On OTC With Rare Diseases Split

By shifting its rare diseases portfolio into a newly-created affiliate, HRA Pharma is signalling its intention to become a force in the global consumer healthcare market. 
France International Health

J&J’s Aveeno Hair-Care Relaunch Per Vogue Model Helps Drive Consumer Q2 Improvements

Company leadership has said that Vogue International – the maker of OGX and Maui Moisture hair care that J&J acquired in 2016 – would serve as a model for innovations across other brands. Strategy appears to be paying off, contributing to gains in J&J's Consumer division, which also benefited in the second quarter from Zyrtec allergy treatment and children’s Tylenol and Motrin.

Sales & Earnings Business Strategies Advertising, Marketing & Sales

Teva Divests US OTC Store Brand Portfolio to PL Developments

Israel's Teva has trimmed its OTC portfolio by offloading its US store brands to PL Developments.
United States Health Business Strategies

Deals

Set Alert for Deals {Health}

Latest From Health & Deals

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
Business Strategies Sales & Earnings

Hermes Grows In Germany With Krewel's OTC Portfolio

Hermes Arzneimittel will grow its share of Germany's OTC market by snapping up a portfolio of consumer health lines from Krewel Meuselbach.
Germany Health

Infant Formula Woes Turn Perrigo's Q2 Sour Despite Solid Americas’ OTC Sales

Perrigo reports 4% Q2 sales growth for OTC drugs in the Americas region was offset by nearly 15% drop in infant formula sale. Total consumer sales in the Americas slipped 2.5% to $582m, but CEO Murray Kessler says brighter days are ahead on benefits from Ranir oral care acquisition.

Sales & Earnings OTC Drugs
See All

Strategy

Set Alert for Business Strategy {Health}

Latest From Health & Business Strategies

NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications

GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from the first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.

OTC Drugs Regulation

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
Business Strategies Sales & Earnings

Consumer Health Executive Decisions: Karp Directs CHPA Health Policy, Pink's Husband Inspires CBD Line, More

Marina Karp joins CHPA as its first director of health policy; UFC welterweight Colby Covington signs on with Cannafornia CBD; "body activist" Ashley Graham is an Olly Nutrition brand ambassador; and Pink's husband, Carey Hart, inspires Next Green Wave's CBD line.

Canada United States
See All

Sales & Earnings

Set Alert for Sales & Earnings {Health}

Latest From Health & Sales & Earnings

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
Business Strategies Sales & Earnings

Consumer Health Results Roundup: Genomma, Ipsen And Taisho

Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.
Sales & Earnings OTC Drugs

Infant Formula Woes Turn Perrigo's Q2 Sour Despite Solid Americas’ OTC Sales

Perrigo reports 4% Q2 sales growth for OTC drugs in the Americas region was offset by nearly 15% drop in infant formula sale. Total consumer sales in the Americas slipped 2.5% to $582m, but CEO Murray Kessler says brighter days are ahead on benefits from Ranir oral care acquisition.

Sales & Earnings OTC Drugs
See All

Litigation

Set Alert for Legal Issues {Health}

Latest From Health & Legal Issues

Bayer Stands By Iberogast As German Court Investigates Manslaughter Case

Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”  

Health OTC Drugs

Application Deadline Ordered To Stop Vaping Industry Evasion Of FDA Approval

"Balancing the need to address the existing public health crisis among today’s youth ... and the need to avoid creating an additional public health crisis if e-cigarette availability dropped so precipitously as to push users to combusted tobacco products," Judge Paul Grimm sets a May 2020 PMTA deadline for vaping products, noting the industry’s "lack of effort to obtain approval without an imminent deadline."

OTC Drugs FDA

GSK Admits Voltaren Marketing Misled Australian Consumers, Now Facing Financial Penalty

GSK has admitted misleading Australian consumers with the marketing of its Voltaren range by claiming Osteo Gel was specifically formulated for treating osteoarthritis conditions, and was more effective than Emulgel to treat those conditions, when the two products were identically formulated. While a change to Osteo Gel's packaging has since satisfied Australia's Federal Court, GSK is still facing a financial penalty for its earlier conduct.
Legal Issues Ad Campaigns
See All
UsernamePublicRestriction

Register